ClinicalTrials.Veeva

Menu
N

Northeast Clinical Research Center | Bethlehem, PA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lixivaptan
Bardoxolone Methyl
Selonsertib
BION-1301
Pegcetacoplan
UDCA
Iron
Sirolimus
Sofosbuvir
Ribavirin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 41 total trials

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients (FACT)

A Multicenter, Comparative Safety and Efficacy Study of Acthar gel alone or in combination with oral Tacrolimus to reduce urinary proteinuria in pati...

Active, not recruiting
Fibrillary Glomerulonephritis
Drug: Acthar Gel 80 UNT/ML Injectable Solution

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

Enrolling
Immunoglobulin A Nephropathy
IgA Nephropathy
Drug: Placebo
Drug: BION-1301

Primary Objectives* To assess the safety and tolerability of RGLS8429* To assess the impact of RGLS8429 on ADPKD biomarkersSecondary Objectives* To a...

Enrolling
ADPKD
Polycystic Kidney, Autosomal Dominant
Drug: Placebo
Drug: RGLS8429

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegce...

Active, not recruiting
Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative Glomerulonephritis
Drug: Pegcetacoplan

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting
End-Stage Renal Disease
End-Stage Kidney Disease
Drug: MK-2060
Drug: Placebo

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients wi...

Active, not recruiting
Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative Glomerulonephritis
Other: Placebo
Drug: Pegcetacoplan

This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease.

Active, not recruiting
Kidney Diseases
Diagnostic Test: Renasight

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting
IgA Nephropathy
Drug: BION-1301 Multiple Doses
Drug: Placebo Multiple Doses

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling
Primary Biliary Cirrhosis
Drug: Seladelpar 5 mg Capsule
Drug: Seladelpar 10 mg Capsule

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

P
Reata Pharmaceuticals logo
A
A
Bristol-Myers Squibb (BMS) logo
C
CymaBay Therapeutics logo
Gilead Sciences logo
Ardelyx logo
Baxalta logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems